ASH 2025 highlighted groundbreaking advancements in multiple myeloma treatment, focusing on bispecific T-cell antibodies for improved patient outcomes.
Hans C. Lee, MD
Articles by Hans C. Lee, MD
Hans C. Lee, MD, discusses the toxicity seen with the BCMA/CD3 bispecific antibody linvoseltamab for patients with relapsed/refractory multiple myeloma.